Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder Bipolar disorder (BPD) is a common and severe mood disorder that affects more than 2 million adults in the USA (1, 2). BPD is associated with increased risk of suicide and a high socioeconomic burden. Although the clinical features of BPD have long been recognized (3), the disease mechanism(s) remain(s) unknown (4), and treatment resistance is high (1, 5) .
Results: Both CK isoforms were downregulated in BPD. Furthermore, mRNA transcripts for oligodendrocyte-specific proteins were downregulated in the DLPFC, whereas the mRNA for the neuronspecific protein microtubule-associated protein 2 was downregulated in the HIP.
Conclusion:
Although some of the downregulation of CK might be explained by cell loss, a more general mechanism seems to be responsible. The downregulation of CK transcripts, if translated into protein levels, could explain the reduction of high-energy phosphates previously observed in BPD. temporal lobes of bipolar subjects (8) (9) (10) (11) ; postmortem studies in the human hippocampus (HIP) of BPD subjects showed a decrease in the expression of nuclear genes coding for mRNAs of the mitochondrial respiratory chain (12) ; and studies in lymphoblastoid cell lines showed a downregulation of the mitochondrial complex I subunit gene, NDUFV2 (24-kDa subunit of the mitochondrial NADH:ubiquinone oxidoreductase), and different haplotype frequencies of four polymorphisms in the upstream region of NDUFV2 (13, 14) .
Creatine kinase (CK) is the enzyme responsible for the reversible transfer of the N-phosphoryl group from PCr to ADP to yield ATP and creatine (Cr) (15) (16) (17) . In tissues with high energy demands, such as the brain, CK serves two purposes: the first is to shuttle phosphate groups from the site of energy production, the mitochondria, to sites of energy consumption, such as ATP-dependent ion pumps and neurotransmitter transporters in neurons and glia (18) . The second function is to retrieve ATP from PCr during periods of intense energy demand (16) . Four CK isoforms are expressed in humans: the first two, brain (CKB) and muscle (CKM), are the cytosolic CK isoenzymes, which are found as homo-or heterodimers at sites of energy consumption; the other two are the mitochondrial isoforms, mitochondrial 1 ubiquitous (CKMt1), and mitochondrial 2 sarcomeric (17) . In the dorsolateral prefrontal cortex (DLPFC) and HIP, the principal CK isoforms are CKB (as the homomer CK-BB) and CKMt1 (19, 20) . CKB is expressed at high levels in oligodendrocytes and astroglia and to a lesser extent in neurons, while CKMt1 is expressed in the mitochondria of all cell types, but with the highest levels in neurons (20, 21) .
Given the reduced PCr levels observed in magnetic resonance spectroscopy studies (11, 22) , we decided to examine the expression levels of mRNA transcripts coding for CKB and CKMt1 in the DLPFC and HIP in the postmortem brain of BPD, schizophrenia (SZ), and control subjects.
Materials and methods

Sample selection and tissue processing
Gene regulation was examined by real-time quantitative polymerase chain reation (PCR) (qPCR; HIP, DLPFC) and by microarrays (HIP) in three study groups: healthy controls, subjects with BPD, and subjects with SZ. Brain specimens were obtained from the Harvard Brain Tissue Resource Center (HBTRC; McLean Hospital, Belmont, MA, USA). Subjects were matched for age, postmortem interval, gender, brain hemisphere and storage time. All diagnoses were established by two psychiatrists at the HBTRC via retrospective review of all available medical records and extensive questionnaires about social and medical history completed by family members of the donors. The criteria of Feighner et al. (23) were applied for the diagnosis of SZ and that of the DSM-IV (24) for the diagnosis of schizoaffective disorder and BPD. Probands with a documented history of substance dependence or neurological illness were excluded from the study.
One hemisphere of each brain underwent a comprehensive neuropathological examination, and only brains with no evidence of stroke, tumor, infection, or neurodegenerative changes were used in the study. Microarray analysis of the HIP was carried out in 10 control subjects, 9 subjects with BPD, and 8 subjects with schizophrenia (12) . For qPCR of the HIP, an independent RNA extraction was performed on samples for which tissue was still available at the HBTRC, yielding seven triplets (control, BPD, SZ; Table 1 ). For qPCR analysis of the DLPFC, nine controls, nine BPD subjects, and eight SZ subjects were obtained (Table 1) . For procedures of the HBTRC see http://www.brainbank.mclean.org/.
Treatment of rats and processing of rat tissue
Male Sprague-Dawley rats (Taconic Farms, Germantown, NY, USA), 200-225 g, were fed 0.15% lithium carbonate chow or control chow balanced for nutrient content (Harlan Teklad, Madison, WI, USA). The colony room was maintained on a 12-h light-dark cycle. Rats were provided water and 450 mM NaCl solution. On day 15 of lithium chow, rats were decapitated, brains removed and immediately frozen in isopentane/dry ice. Hippocampi were dissected on a freezing microtome, and RNA was extracted and prepared for gene expression microarray analysis applying the same protocol used for the human studies.
Gene array data analysis
Affymetrix HG-U95Av2 arrays were used in the human study, and RAE230A arrays were used in the rat study. (For specifics of tissue and RNA preparation for the Affymetrix GeneChips see 12, 25.) RMAexpress was used for background adjustment, normalization, and computation of gene expression summary values (http://stat-www. berkeley.edu/users/bolstad/RMAExpress/RMA Express.html), (26, 27) . The dChip program (http://www.dchip.org) (28) and GenMAPP (http://www.genmapp.org) (29) were used for Reduced creatine kinase mRNA in BPD The PCR cycling conditions were 95°C for 7 min followed by 39 cycles of 94°C for 10 s, 55°C for 15 s, 72°C for 20 s, and 73-82°C (depending on product melt temperature) for 2 s. A melt curve analysis was performed at the end of each PCR experiment to verify product specificity for each reaction. Dilution curves were generated for each experiment by diluting cDNA four times from a control sample with a ratio of 1:5, yielding a dilution series of 1.00, 0.2, 0.04, 0.008, and 0.0016. The logarithm of the dilution value was plotted against the cycle threshold value to give a standard curve. Blanks were included in each dilution curve to control for cross-contamination. Dilution curves, blanks, and samples were assayed in duplicates on the same plate. Reported values were normalized to the internal control human filamin A alpha (Table 2) , an actin binding protein that was not regulated in the gene array experiment or the qPCR analysis.
Results
Microarray data revealed a significant decrease (p < 0.05) of the CKB and CKMt1 transcript in the HIP in BPD (Fig. 1A) but not in SZ (Fig. 1B) . To further examine the expression levels of the CK isoforms in BDP and SZ, qPCR was performed on postmortem tissue from the DLPFC and HIP. A subset of the same samples used to generate the microarray data was used for qPCR analysis, and downregulations of CKB and CKMt1 (p ¼ 0.07; not significant) was confirmed in the HIP in BPD ( Fig. 2A) , in contrast to SZ (Fig. 2B) . Moreover, similar downregulations of CKB and CKMt1 were observed in the DLPFC in BPD (Fig. 2C ), but not in SZ (Fig. 2D) . However, the data indicate that SZ brains might follow a similar, albeit weaker, trend. Power analysis revealed that a sample size of 26 (CKMt1) to 44 (CKB) samples could potentially yield significant downregulations of CK isoforms in the HIP in SZ, and a sample size of 33 (CKB) to 43 (CKMt1) in the DLPFC. CKMt1 is expressed predominantly in neurons, while CKB is expressed predominantly in oligodendrocytes and astrocytes (20, 21, 33) . Because some studies of BPD have shown a reduction in glial markers and glial density (34) (35) (36) and others have shown a reduction in neuronal size and number (36) (37) (38) , the downregulation of CKB might be a consequence of glial loss, or, conversely, the downregulation of CKMt1 might indicate neuronal cell loss. Therefore, we used qPCR to examine expression levels of markers for astrocytes (glial fibrillary acidic protein), oligodendrocytes (myelin-associated glycoprotein; gelsolin, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3, ERBB3; and myelin basic protein) and neurons (doublecortin and microtubule-associated protein 2, MAP2) in the HIP (Fig. 3A) and DLPFC (Fig. 3B) . Doublecortin was similar to control in both brain areas, whereas in the HIP, MAP2 was downregulated. The data imply that the downregulation of CKMt1 in the DLPFC is not due to neuronal cell death, but leaves the question open for the HIP (Fig. 4) . In agreement with previous observations, several oligodendrocyte markers were significantly downregulated in the DLPFC in BPD ( Fig. 3; 34) . Thus, it cannot be ruled out that the downregulation of CKB in the DLPFC in BPD was augmented by a decrease of the glial cell population.
In order to examine the potential effect of mood stabilizers on the expression of transcripts of CKB, CKMt1 and neuronal and glial markers, we fed rats lithium chow for 15 days and performed a gene expression microarray analysis (Table 3) . Except for ERBB3, no significant changes were found, suggesting that treatment might not be responsible for the observed findings.
Discussion
The Cr shuttle plays a critical role in cellular energy storage and regulation (15, 16, 39) , and research suggests that BPD might be accompanied by reduced PCr levels and altered mitochondrial function. Spectroscopic imaging studies have shown reductions of PCr in BPD and depression (8, 11, 22, (40) (41) (42) (43) . In a study of geriatric depression, remission was accompanied by an increase in PCr concentration (40) . The decreased PCr concentration observed in BPD was interpreted to be a result of mitochondrial dysfunction (11) . This interpretation was based on increased lactate levels observed in BPD subjects, as increases in lactate levels are associated with mitochondrial myopathies and other syndromes of energy impairment (44) . Concordant with this interpretation, a downregulation of nuclear mRNAs coding for proteins of the mitochondrial respiratory chain was observed in the HIP in BPD subjects (12) . In this study we demonstrate that transcripts of CK isoforms are downregulated in the same patients that showed a downregulation of genomic mitochondrial transcripts (12) , raising the possibility that the reductions in PCr levels and downregulations of CK and mitochondrial respiratory chain transcripts are linked. It has been demonstrated that mice lacking CKB exhibit diminished open-field habituation and delayed acquisition of spatial tasks (45) , while mice lacking CKMt display a reduced acoustic startle response and lack of prepulse inhibition in addition to the deficits seen in CKB knockout mice (46, 47) . These mice did not show any gross abnormalities of brain structure or of mitochondrial ultrastructure; in fact, the mice were Ôovertly normalÕ and Ôrather sophisticated analysis and challenging conditions were needed to reveal (these deficits)Õ (48) . Thus, while the complete removal of a CK isoform does produce measurable behavioral deficits, it does not create overt symptoms, and a downregulation of CK transcripts, if translated into lower protein levels, might produce a subtle pathology that could be compatible with BPD.
In contrast to the decreased expression of CK mRNA observed in our study in the brain, increased levels of CK protein were observed in cerebrospinal fluid and serum of BPD patients immediately after an acute episode (49) (50) (51) . Increased serum levels of CK protein are likely the muscle isoform and may indicate muscle damage (52, 53) ; however, studies have shown that isometric muscle tension cannot account for the large spike in serum CK protein levels following an elevated state in BPD and SZ (54) . Increased CNS levels of CK protein might indicate cell death in the brain (49, (55) (56) (57) . Our data cannot refute a hypothesis of neuronal cell death in the HIP or loss of glia in the DLPFC leading to increased CK protein during an acute episode, and decreased levels of CK mRNA due to lower cell numbers after the episode and in the euthymic state. A reduction in glial cell population would also have an adverse effect on the Cr shuttle system, since only oligodendrocytes and astroglia express the enzyme responsible for Cr synthesis, suggesting that glia supplies neurons with Cr (20) .
However, cell death is not a satisfactory explanation for reduced CK mRNA levels. First, the particular distribution of CKB and CKMt1 between neurons and glia would suggest that a loss of neurons should be mostly evident as a loss of CKMt1 transcripts, whereas a loss of glia would be reflected in a loss of CKB transcripts. Loss of one cell type would lead to a relative increase in the remaining cell type in a given sample, thus decrease in one CK type should lead to an increase in the other. We did see both isoforms reduced in both brain areas. Second, the level of only one of two neuron-specific genes, MAP2, was reduced in the HIP, thus providing weak support for cell death in this brain area. While we cannot exclude that cell death might be contributing to the reduced transcript levels of CK isoforms, the data point more likely to a generalized disturbance of energy regulation in BPD.
Although we took great care in matching the samples, human postmortem studies offer only limited experimental control. We excluded subjects who died under respiratory distress, were on a ventilator or had otherwise prolonged agonal events, but variability in mode of death beyond our control could have influenced the results. Disease-specific treatment is another concern: because BPD patients were treated with mood stabilizers, we examined in a rat model if lithium treatment affects transcript levels of CK isoforms in the HIP. Lithium treatment did not affect CK transcript levels nor transcript levels of neuronal or glial genes, although we did find a downregulation of ERBB3. However, ERBB3 was represented by two different probe sets on the array, only one of which was changed. Because of this discrepancy, because ERBB3 was only one of five glial-specific transcripts, and because ERBB3 was not altered in the human HIP, we conclude that treatment with mood stabilizers is not responsible for the observed downregulations of glial-and neuron-specific transcripts, nor of CK.
Our data lend further support to altered energy systems in BPD. Whether this change is cause or consequence of the disorder cannot be deduced from the results. However, the question of cause and consequence might not be of major significance for treatment strategies, since a negative impact, be it primary or secondary, would always benefit from treatment. In conclusion, the Ôenergy hypothesis of BPDÕ deserves closer scrutiny and further examination as it has the potential to alter therapeutic approaches to the disease.
